Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$5.11
+5.1%
$8.40
$3.80
$47.80
$7.70M-1.2762,381 shs99,836 shs
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$0.66
-1.6%
$0.94
$0.63
$3.12
$2.34M1.02211,613 shs78,807 shs
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$4.93
+0.2%
$4.82
$1.62
$29.28
$9.40M1.814,631 shs11,608 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.85
-9.2%
$2.08
$1.35
$26.83
$18.18M0.610.67 million shs1.83 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
+2.97%+4.52%-43.96%-37.21%-87.21%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-1.79%-2.73%-35.31%-35.62%-72.74%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+2.69%+0.80%+4.87%-7.35%+492,899,900.00%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
+7.17%+115.07%+113.61%+7.53%-82.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.0273 of 5 stars
3.55.00.00.02.71.70.0
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
1.9815 of 5 stars
3.52.00.00.01.10.01.3
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
1.6187 of 5 stars
3.50.00.00.01.60.00.6
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.3624 of 5 stars
3.52.00.04.62.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.00
Buy$31.00506.65% Upside
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
3.00
Buy$14.002,018.00% Upside
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
3.00
Buy$10.00102.84% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$71.172,397.08% Upside

Current Analyst Ratings Breakdown

Latest CANF, ACXP, DWTX, and XFOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$7.00 ➝ $3.50
8/12/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$31.00
7/29/2025
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/15/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$160.00
(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$2.25 per shareN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$674K3.47N/AN/A$1.76 per share0.38
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/A($9.48) per shareN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M6.45N/AN/A$0.69 per share4.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$14.10M-$10.69N/AN/AN/AN/A-436.83%-192.25%N/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$12.35M-$18.78N/AN/AN/AN/AN/A-27.41%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M-$14.84N/AN/AN/A-311.15%-375.31%-72.87%N/A

Latest CANF, ACXP, DWTX, and XFOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$1.26-$1.99-$0.73-$1.99N/AN/A
8/11/2025Q2 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$2.00-$1.89+$0.11-$1.89N/AN/A
8/8/2025Q2 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.53-$3.47+$1.06-$3.47$1.62 million$1.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
2.38
1.93
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/A
7.80
7.43
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
19.10
3.19
3.58

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
9.05%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
20.30%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
3.90%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
31.58 million1.26 millionOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
83.54 millionN/ANot Optionable
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
51.91 million1.84 millionN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals Closes $85M Private Placement Deal
X4 Pharmaceuticals Announces $60M Equity Financing
X4 Pharmaceuticals secures $60M PIPE financing
X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$5.11 +0.25 (+5.14%)
Closing price 04:00 PM Eastern
Extended Trading
$5.04 -0.08 (-1.47%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$0.66 -0.01 (-1.64%)
Closing price 03:47 PM Eastern
Extended Trading
$0.67 +0.01 (+0.76%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Dogwood Therapeutics stock logo

Dogwood Therapeutics NASDAQ:DWTX

$4.93 +0.01 (+0.20%)
Closing price 03:54 PM Eastern
Extended Trading
$4.95 +0.02 (+0.49%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$2.85 -0.29 (-9.24%)
Closing price 04:00 PM Eastern
Extended Trading
$2.82 -0.03 (-0.91%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.